Know Cancer

or
forgot password

Vaccination With Autologous Dendritic Cells Pulsed With Allogenous Melanoma Lysate (MelCancerVac) for Treatment of Patients With Advanced Colorectal Cancer


Phase 2
25 Years
75 Years
Not Enrolling
Both
Colorectal Neoplasms

Thank you

Trial Information

Vaccination With Autologous Dendritic Cells Pulsed With Allogenous Melanoma Lysate (MelCancerVac) for Treatment of Patients With Advanced Colorectal Cancer


Inclusion Criteria:



- Verified cancer of colon or rectum

- No chemo- or radiation therapy in 6 weeks

- Performance status 0, 1, or 2 (WHO criteria)

- Adequate function of the kidneys, liver, lungs, and heart

- Adequate function of the hematopoietic system and the coagulation system

- Negative pregnancy test and adequate birth control for fertile women

Exclusion Criteria:

- Pregnancy

- Uncontrolled infection

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label

Principal Investigator

Anders Fischer, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University Hospital Gentofte

Authority:

Denmark: Danish Medicines Agency

Study ID:

2612-1970

NCT ID:

NCT00311272

Start Date:

November 2004

Completion Date:

September 2007

Related Keywords:

  • Colorectal Neoplasms
  • dendritic cells
  • antigens, neoplasm
  • Neoplasms
  • Colorectal Neoplasms

Name

Location